CompletedPhase 2

Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

China102 participantsStarted 2020-12-07

Plain-language summary

This is an open-label, phase II，multi-center study to evaluate the efficacy, safety and tolerability of KN026 in combination with KN046 in subjects with HER2-positive solid tumors.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓Bone marrow function met the following criteria within 7 days prior to initial administration: Hemoglobin ≥90 g/L; Neutrophil absolute count ≥1.5 x 109/L; Platelet count ≥100x 109/L; INR or PT≤1.5x ULN, and aPTT≤ 1.5x ULN;

What they're measuring

Objective response rate (ORR )

Timeframe: Throughout the duration of the study; up to 2 years

Duration of response (DOR)

Timeframe: Throughout the duration of the study; up to 2 years

Trial details

NCT IDNCT04521179

SponsorJiangsu Alphamab Biopharmaceuticals Co., Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-01-12

View on ClinicalTrials.gov More HER2-positive Solid Tumors trials